<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00779805</url>
  </required_header>
  <id_info>
    <org_study_id>016/ PSEUD-120/ 04</org_study_id>
    <nct_id>NCT00779805</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Pseudoephedrine HCl 120 mg ER Tablets Under Fed Conditions</brief_title>
  <official_title>An Open Label, Balanced, Randomised, Two-Treatment, Two-Period, Two-Sequence, Single-Dose, Crossover Bioavailability Study on Pseudoephedrine Hydrochloride Formulations Comparing Pseudoephedrine Hydrochloride 120 mg ER Tablets of Ranbaxy Laboratories With Sudafed 120 mg ER Tablets of Pfizer Consumer Health Care in Healthy, Adult, Human Subjects Under Fed Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ranbaxy Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ranbaxy Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study was to compare the single dose oral bioavailability of&#xD;
      Pseudoephedrine hydrochloride 120 mg ER tablets of Ranbaxy with Sudafed 120 mg ER tablets of&#xD;
      Pfizer Consumer Health Care in healthy, adult, human subjects under fed conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was an open label, balanced, randomized, two-treatment, two-period, two-sequence,&#xD;
      single dose crossover bioavailability study planned on 40 healthy, adult, human subjects&#xD;
      under fed conditions.&#xD;
&#xD;
      A total of forty (40) healthy, adult, human subjects were admitted in the study to allow the&#xD;
      dosing in the first period. Out of the forty subjects, only thirty eight (38) subjects&#xD;
      completed both the periods of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">October 2004</completion_date>
  <primary_completion_date type="Actual">June 2004</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence</measure>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pseudoephedrine hydrochloride 120 mg ER tablets of Ranbaxy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sudafed 120 mg ER tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pseudoephedrine hydrochloride 120 mg ER tablets</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be in the age range of 18 - 45 years&#xD;
&#xD;
          -  Be neither over weight nor under weight for his/ her height as per the Life Insurance&#xD;
             Corporation of India height/ weight chart for non-medical cases&#xD;
&#xD;
          -  Have voluntarily given written informed consent to participate in this study&#xD;
&#xD;
          -  Be of normal health as determined by medical history and physical examination of the&#xD;
             subjects performed within 14 days prior to the commencement of the study&#xD;
&#xD;
          -  If female and:&#xD;
&#xD;
          -  Of child bearing potential is practicing an acceptable method of birth control for the&#xD;
             duration of the study as judged by the investigator (s), such as condoms, foams,&#xD;
             jellies, diaphragm, intrauterine device (IUD), or abstinence; or&#xD;
&#xD;
          -  Is postmenopausal for at least 1 year; or&#xD;
&#xD;
          -  Is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or&#xD;
             hysterectomy)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of allergy to Pseudoephedrine or other sympathomimetic drugs&#xD;
&#xD;
          -  History of intake of any sympathomimetic drugs and glucocorticoids during a period of&#xD;
             15 days prior to day 1 of this study.&#xD;
&#xD;
          -  Concurrent use of monoamine oxidase inhibitor (MAOI) drugs within 14 days prior to day&#xD;
             1 of this study&#xD;
&#xD;
          -  Any evidence of organ dysfunction or any clinically significant deviations from the&#xD;
             normal, in physical or clinical determinations&#xD;
&#xD;
          -  Presence of disease markers of HIV 1 or 2, hepatitis B or C viruses or syphilis&#xD;
             infection&#xD;
&#xD;
          -  Female volunteers demonstrating a positive pregnancy test&#xD;
&#xD;
          -  Female volunteers who are currently breastfeeding&#xD;
&#xD;
          -  Presence of values which are significantly different from normal reference ranges (as&#xD;
             defined in appendix 5) and/ or judged clinically significant for serum creatinine,&#xD;
             blood urea nitrogen, serum aspartate aminotransferase (AST), serum alanine&#xD;
             aminotransferase (ALT), serum alkaline phosphatase, serum bilirubin, plasma glucose or&#xD;
             serum cholesterol&#xD;
&#xD;
          -  Clinically abnormal chemical and microscopic examination of urine defined as presence&#xD;
             of RBC, WBC (&gt;4/ HPF), glucose (positive) or protein (positive)&#xD;
&#xD;
          -  Clinically abnormal ECH or chest X-ray&#xD;
&#xD;
          -  History of serious gastrointestinal, hepatic, renal, pulmonary, neurological or&#xD;
             hematological diseases or glaucoma&#xD;
&#xD;
          -  History of cardiovascular disorders (including hypertension), endocrine disorders,&#xD;
             hyperthyroidism, diabetes mellitus, prostatic hypertrophy, palpitations, insomnia,&#xD;
             tremors or bronchial asthma&#xD;
&#xD;
          -  History of any psychiatric illness which may impair the ability to provide written&#xD;
             informed consent&#xD;
&#xD;
          -  Regular smokers who smoke more than 10 cigarettes daily or have difficulty abstaining&#xD;
             from smoking for the duration of each study period.&#xD;
&#xD;
          -  History of drug dependence or excessive alcohol intake on a habitual basis of more&#xD;
             than 2 units of alcoholic beverages per day (1 unit equivalent to half pint of beer or&#xD;
             1 glass of wine or 1 measure of spirit) or have difficulty in abstaining for the&#xD;
             duration of each study period&#xD;
&#xD;
          -  Use of any enzyme modifying drugs within 30 days prior to day 1 of this study&#xD;
&#xD;
          -  Participation in any clinical trail within 12 weeks preceding day 1 of this study&#xD;
&#xD;
          -  Subjects who, through completion of this study, would have donated and / or lost more&#xD;
             than 350 mL of blood in the past 3 months.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ranbaxy CPU</name>
      <address>
        <city>Gurgaon</city>
        <state>Haryana</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.ranbaxy.com</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://dailymed.nlm.nih.gov/dailymed/about.cfm</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.fda.gov/opacom/7alerts.html</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2008</verification_date>
  <study_first_submitted>October 23, 2008</study_first_submitted>
  <study_first_submitted_qc>October 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2008</study_first_posted>
  <last_update_submitted>October 23, 2008</last_update_submitted>
  <last_update_submitted_qc>October 23, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. Tausif Monif</name_title>
    <organization>Ranbaxy Research Labs</organization>
  </responsible_party>
  <keyword>Bioequivalence Pseudoephedrine hydrochloride 120 mg ER tablets</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malnutrition</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pseudoephedrine</mesh_term>
    <mesh_term>Ephedrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

